Wu et al[20] and Novello et al[18] showcased that ALK-positive resected NSCLC alectinib had significantly decreased rates in CNS metastases treated with platinum-based chemotherapy or alectinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.